Sulfobutyl ether 7 β-cyclodextrin (SBE 7 β-CD) carbamazepine complex: Preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity

AAPS PharmSciTech

Volumn 12, Issue 4, 2011, Pages 1163-1175

  Jain, Ankitkumar S ^a   Date, Abhijit A ^a   Pissurlenkar, Raghuvir R S ^a   Coutinho, Evans C ^a   Nagarsenker, Mangal S ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

anti epileptic activity; carbamazepine; poor water solubility; spray drying; sulfobutyl ether 7 cyclodextrin

Indexed keywords

CARBAMAZEPINE; CYCLODEXTRIN; PENTETRAZOLE; SULFOBUTYL ETHER7 BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EPILEPSY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SPRAY DRYING; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG COMPOUNDING; EPILEPSY; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; PENTYLENETETRAZOLE; SOLUBILITY; SPECTROPHOTOMETRY, INFRARED; TECHNOLOGY, PHARMACEUTICAL; X-RAY DIFFRACTION;

EID: 83555176134     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9685-z     Document Type: Article

References (27)

1. J Bauer BM Monika M Reuber 2009 Treatment strategies for focal epilepsy Expert Opin Pharmacother 10 743 53 19351225 10.1517/14656560902772328 1:CAS:528:DC%2BD1MXktFCmt7Y%3D
2. S Sethia E Squillante 2004 Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods Int J Pharm 272 1 10 15019063 10.1016/j.ijpharm.2003.11.025 1:CAS:528:DC%2BD2cXhs1Giurw%3D (Pubitemid 38293005)
3. N Barakat S Omar A Ahmed 2006 Carbamazepine uptake into rat brain following intra-olfactory transport J Pharm Pharmacol 58 63 72 16393465 10.1211/jpp.58.1.0008 1:CAS:528:DC%2BD28XpsFKhtbk%3D (Pubitemid 43041997)
4. G Kumineka J Kratza R Ribeiroa R Kelmanna B de Araújob H Teixeirab, et al. 2009 Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs Int J Pharm 378 146 8 10.1016/j.ijpharm.2009.05.055
5. N Zerrouk C Chemtob P Arnaud S Toscani J Dugue 2001 In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions Int J Pharm 225 49 62 11489554 10.1016/S0378-5173(01)00741-4 1:CAS:528:DC%2BD3MXlslant7s%3D (Pubitemid 32728199)
6. H El-Zein L Riad A Abd El-Bary 1998 Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation Int J Pharm 168 209 20 10.1016/S0378-5173(98)00093-3 1:CAS:528:DyaK1cXksF2ls70%3D (Pubitemid 28349962)
7. ME Brewster T Loftsson 2007 Cyclodextrins as pharmaceutical solubilizers Adv Drug Deliv Rev 59 645 66 17601630 10.1016/j.addr.2007.05.012 1:CAS:528:DC%2BD2sXpsFGks7g%3D (Pubitemid 47299263)
8. M Fukuda D Miller N Peppas J McGinity 2008 Influence of sulfobutyl ether β-cyclodextrin (Captisol®) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion Int J Pharm 350 188 96 17920217 10.1016/j.ijpharm.2007.08.038 1:CAS:528:DC%2BD1cXhtlGntb8%3D
9. Y Nagase M Hirata H Arima S Tajiri Y Nishimoto F Hirayama, et al. 2002 Protective effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced hemolysis in vitro J Pharm Sci 91 2382 9 12379923 10.1002/jps.10236 1:CAS:528:DC%2BD38XosF2htb8%3D (Pubitemid 35231201)
10. AM Tötterman NGM Schipper DO Thompson JP Mannermaa 1997 Intestinal safety of water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells J Pharm Pharmacol 49 43 8 9120769 10.1111/j.2042-7158.1997.tb06750.x (Pubitemid 27051029)
11. K Okimoto A Ohike R Ibuki O Aoki N Ohnishi T Irie, et al. 1999 Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7 m-beta-CD Pharm Res 16 549 54 10227711 10.1023/A:1018827214223 1:CAS:528:DyaK1MXisFyru7c%3D (Pubitemid 29191301)
12. R Kale M Saraf P Tayade 2005 Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat Eur J Pharm Biopharm 60 39 46 10.1016/j.ejpb.2004.12.005 (Pubitemid 40545859)
13. R Kale P Tayade M Saraf A Juvekar 2008 Molecular encapsulation of thalidomide with sulfobutyl ether-7 beta-cyclodextrin for immediate release property:enhanced in vivo antitumor and antiangiogenesis efficacy in mice Drug Dev Ind Pharm 34 149 56 18302033 10.1080/03639040701484486 1:CAS:528: DC%2BD1cXisVSqurs%3D (Pubitemid 351317143)
14. JS Smith RJ MacRae MJ Snowden 2005 Effect of SBE-7-β-cyclodextrin complexation on carbamazepine release from sustained release beads Eur J Pharm Biopharm 60 73 80 15848059 10.1016/j.ejpb.2004.12.001 1:CAS:528: DC%2BD2MXjsVehtr8%3D (Pubitemid 40545863)
15. T Higuchi KA Connors 1965 Phase-solubility techniques Adv Anal Chem Instrum 4 117 212 1:CAS:528:DyaF2MXktlGitrg%3D
16. A Figueiras A Carvalho L Ribeiro J Torres-Labandeira F Veiga 2007 Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin Eur J Pharm Biopharm 67 531 9 17451924 10.1016/j.ejpb.2007.03.005 1:CAS:528: DC%2BD2sXovFyrsrc%3D (Pubitemid 47211912)
17. P Mark L Nilsson 2001 Structure and dynamics of the TIP3P, SPC, and SPC/E Water models at 298 K J Phys Chem A 105 9954 60 10.1021/jp003020w 1:CAS:528:DC%2BD3MXntlWrurs%3D (Pubitemid 35378507)
18. D Quigley MIJ Probert 2005 Constant pressure Langevin dynamics: theory and application Comp Phys Comm. 169 322 5 10.1016/j.cpc.2005.03.072 1:CAS:528:DC%2BD2MXls1yisr4%3D (Pubitemid 40890634)
19. JP Ryckaert G Ciccotti HJC Berendsen 1977 Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes J Comput Phys 23 327 41 10.1016/0021-9991(77)90098-5 1:CAS:528:DyaE2sXktVGhsL4%3D
20. Vogel HG, Vogel WH, Schoelkens BA, Sandow J, Mueller G, Vogel WF, editors. Drug discovery and evaluation: pharmacological assays. New York: Springer; 2008. p. 613.
21. JR Moyano JM Gines MJ Arias AM Robasco 1995 Study of dissolution characteristic of oxazepam via complexation with β-cyclodextrin Int J Pharm 114 95 102 10.1016/0378-5173(94)00220-Y 1:CAS:528:DyaK2MXivVKrtrg%3D (Pubitemid 24377033)
22. B Yang J Lin Y Chen Y Liu 2009 Artemether/hydroxypropyl-beta-cyclodextrin host-guest system: characterization, phase-solubility and inclusion mode Bioorg Med Chem 17 6311 7 19665897 10.1016/j.bmc.2009.07.060 1:CAS:528: DC%2BD1MXhtVenurzN
23. N Zerrouk S Toscani J-M Gines-Dorado C Chemtob R Ceólin J Dugué 2001 Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures Eur J Pharm Sci 12 395 404 10.1016/S0928-0987(00)00168-8 (Pubitemid 32166738)
24. P Blach D Landy S Fourmentin G Surpateanu H Bricout A Ponchel, et al. 2005 Sulfobutyl ether-β-cyclodextrins: promising supramolecular carriers for aqueous organometallic catalysis Adv Synth Catal 347 1301 7 10.1002/adsc.200505051 1:CAS:528:DC%2BD2MXntFCqtbY%3D (Pubitemid 41044821)
25. 1H NMR and molecular modelling studies of bupivacaine hydrochloride complexation with different cyclodextrin derivates Chem Phys Lett 500 347 54 10.1016/j.cplett.2010.10.046 1:CAS:528:DC%2BC3cXhsVWqsbnI
26. A Zoppi MA Quevedo MR Longhi 2008 Specific binding capacity of β-cyclodextrin with cis and trans enalapril: physicochemical characterization and structural studies by molecular modeling Bioorg Med Chem 16 8403 12 18771929 10.1016/j.bmc.2008.08.032 1:CAS:528:DC%2BD1cXhtFantL7K
27. I Klioueva E van Luijtelaar N Chepurnova S Chepurnov 2001 PTZ-induced seizures in rats: effects of age and strain Physiol Behavior. 72 421 6 10.1016/S0031-9384(00)00425-X 1:CAS:528:DC%2BD3MXit1Sitr0%3D (Pubitemid 32234430)